A new analysis being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), finds that around ...

In patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is not associated ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Learn how emerging technologies are enhancing patient engagement and treatment strategies in everyday practice.

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 ...

CEO Andrew Dudum said the funds will allow the company to grow internationally and invest in artificial intelligence.

GLP1 drugs are changing patients eating and grocery shopping habits - 2 News Oklahoma's Cathy Tatom hears how from a patient, ...

Scientists at EPFL and AstraZeneca have developed a method to map the atomic-level structure of amorphous drugs, demonstrated ...

A new analysis being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), finds that around half of the 100 top ...

Data from a Swedish clinic suggests that GLP-1 drugs can be effective in managing severe obesity in children, offering a ...

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.